Daniel Lochner - 02 Sep 2021 Form 4 Insider Report for Oyster Point Pharma, Inc.

Role: Chief Financial Officer
Signature: /s/ Brandon Fenn, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 02 Sep 2021
Net transactions value: +$86,325
Form type: 4
Filing time: 07 Sep 2021, 08:03:56 UTC
Previous filing: 30 Aug 2021
Next filing: 02 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OYST	Common Stock	Options Exercise	$86,325	+7,500	+18%	$11.51	49,631	02 Sep 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OYST	Employee Stock Option (Right to Buy)	Options Exercise	$0	-7,500	-4.2%	$0.000000	169,841	02 Sep 2021	Common Stock	7,500	$11.51	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Option was granted on July 25, 2019 under the Oyster Point Pharma, Inc. 2016 Equity Incentive Plan. One quarter of the total number of shares subject to the option vested on July 22, 2020, and one forty-eighth of the total number of shares continue to vest monthly thereafter, subject to continued service to the Issuer through each such vesting date. The award is subject to vesting acceleration under certain circumstances.

Content

The Option was granted on July 25, 2019 under the Oyster Point Pharma, Inc. 2016 Equity Incentive Plan. One quarter of the total number of shares subject to the option vested on July 22, 2020, and one forty-eighth of the total number of shares continue to vest monthly thereafter, subject to continued service to the Issuer through each such vesting date. The award is subject to vesting acceleration under certain circumstances.